Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Current management of hemophilia A includes prophylaxis with factor VIII (FVIII) replacement every 2 to 3 days. BAX 855, Baxalta’s pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while maintaining hemostat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Konkle, Barbara A., Stasyshyn, Oleksandra, Chowdary, Pratima, Bevan, David H., Mant, Tim, Shima, Midori, Engl, Werner, Dyck-Jones, Jacqueline, Fuerlinger, Monika, Patrone, Lisa, Ewenstein, Bruce, Abbuehl, Brigitt
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2015
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4551361/
https://ncbi.nlm.nih.gov/pubmed/26157075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-630897
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы